id: NEW:pharmaceutical_benefits_scheme_opioid_restriction_to_opioid_overdose_nonfatal_rate
name: Pharmaceutical Benefits Scheme Opioid Subsidy Restriction â†’ Opioid Overdose Nonfatal Rate (ED visits
  per 100k)
from_node:
  node_id: NEW:pharmaceutical_benefits_scheme_opioid_restriction
  node_name: Pharmaceutical Benefits Scheme Opioid Subsidy Restriction
to_node:
  node_id: opioid_overdose_nonfatal_rate
  node_name: Opioid Overdose Nonfatal Rate (ED visits per 100k)
direction: negative
category: political
mechanism_pathway:
- 'Step 1: Tighter restriction criteria for opioid medication subsidization through PBS limit access to
  subsidized opioid prescriptions'
- 'Step 2: Financial and administrative barriers reduce overall volume of opioid prescriptions dispensed'
- 'Step 3: Reduced opioid prescribing decreases population-level exposure to prescription opioids'
- 'Step 4: Lower opioid availability reduces opportunities for misuse, dependence development, and overdose'
- 'Step 5: Opioid-related emergency department presentations decrease among people prescribed opioids'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Suzanne Nielsen et al. 2025. "Prescription opioid supply-restricting policies and
    hospital use by people prescribed opioid medications, Victoria, 2018-22: a controlled interrupted
    time series analysis.." https://doi.org/10.5694/mja2.52713'
  supporting_citations:
  - Additional citations require full-text access - abstract references European post-authorisation study
    register (EUROPAS), EUPAS104005
  doi: 10.5694/mja2.52713
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Tighter restriction criteria for PBS subsidization of opioid medications, implemented June
  2020, contributed to declining opioid-related ED presentations. The combined policy intervention of
  mandatory monitoring and PBS restrictions demonstrated that supply-side policies can reduce opioid-related
  harm.
quantitative_effects:
  sample_size: 179091
structural_competency:
  equity_implications: This mechanism operates through pharmaceutical policy and subsidy structures rather
    than individual decision-making. It addresses the economic and regulatory environment that shapes
    opioid availability. The policy intervention targets systemic factors in medication access rather
    than stigmatizing individuals with opioid use disorders.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.660218'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
